

Antibiotics

David M. Shlaes

Antibiotics

The Perfect Storm

 Springer

David M. Shlaes
Anti-infectives Consulting, LLC
Montauk Avenue 219
06378 Stonington
CT, USA
shlaes.david@earthlink.net

ISBN 978-90-481-9056-0

e-ISBN 978-90-481-9057-7

DOI 10.1007/978-90-481-9057-7

Springer Dordrecht Heidelberg London New York

Library of Congress Control Number: 2010934450

© Springer Science+Business Media B.V. 2010

No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

*To Jan for years of hard work, patience,
understanding, love and support.*



David M. Shlaes MD, PhD has had a 30-year career in anti-infectives spanning academia and industry with a long-standing scientific interest in antimicrobial resistance. In 1991 he was appointed Professor of Medicine at Case Western Reserve University. In 1996, Dr. Shlaes became vice president for Infectious Diseases at Wyeth Research for 6 years, assuming responsibility for the strategic direction for infectious diseases within Wyeth. In 1998 Dr. Shlaes was the cover feature in the April issue of *Business Week* dedicated to antibiotics research. In 2002, Dr. Shlaes became executive vice president, Research and Development for Idenix, Pharmaceuticals, a company located in Cambridge, MA, focused on the discovery and development of antivirals. In 2005, he left Idenix to form a consulting company for the Pharmaceutical Industry (Anti-Infectives Consulting, LLC). He was recently an independent director for Novexel, S.A, an anti-infectives biotech in Paris that was just sold to Astra-Zeneca. He consults for a number of other anti-infective focused biotechs and frequently works with VC firms in the evaluation of anti-infective companies.

Contents

1	The Perfect Storm	1
2	The Miracle	9
3	Resistance	15
	The Basics	15
	Antibiotics for Animals and Crops Lead to Resistance for People	16
	In Our Hospitals, Things Are Getting Critical	20
	Antibiotic Resistance Plus Toxin Production Equals Death	23
	Our Communities are Not Spared	25
	Resistance – Summing Up	27
4	The FDA	29
	We Need Them, but They Have Become Part of the Problem	29
	The FDA Increases Clinical Trial Design Stringency and Costs.	
	Companies Abandon Antibiotic Research	32
	“Mild” Infections Require Placebo-Controlled Trials – Industry	
	Balks	35
	New Antibiotics for Mild Infections Are Forced from the Market	
	While Generic Antibiotics Are Still Approved in the Absence	
	of Placebo-Controlled Trials	38
	The Ketek Scandal	38
	Pneumonia – The New Frontier. New Trial Requirements for	
	Pneumonia Will Make Approval Much More Difficult and	
	Costly and Sometimes Simply Infeasible	41
	The FDA Can Change Its Requirements After Completion	
	of a Trial and then Require New Trials for Approval	44
	The FDA is Regulating Itself Out of the Antibiotics Business	46
	We Need Balance and Perspective from the FDA	47
	The FDA Makes It Difficult for Them to Obtain Good Advice	48
5	Europe	51
6	The Industry	57
	Antibiotics Form a Cornerstone of the Pharmaceutical Industry	57
	Resistance Should Create Opportunities	60

Industry Consolidation Reduces the Effort in Antibiotics	61
Antibiotics Are Not Financially Attractive in the Consolidated Industry	63
Industry Takes a Risk-Averse Approach to Its Clinical Trials, but Deprives Us of the Most Important Information	65
Discovery of New Antibiotics Is Becoming Harder	66
The US Market Share is Stagnant or Shrinking. Will the Industry be Able to Prioritize Ex-US Territories?	67
Research and Development Costs Increase, but Approvals Are Down . .	68
Some Good News for Everyone	69
Antibiotic R&D in Biotech Is Stymied by Late Stage Clinical Trial Costs	71
Biotech Is Still a High-Risk Proposition	73
7 Modest Proposals	77
The Role of Government	77
Government Loves a Task Force	77
Government Can Play Several Important Roles	79
The Transatlantic Taskforce on Antimicrobial Resistance	81
Government-Sponsored Research and Research Tools Are Required . .	81
Industry Incentives Will Probably Also Be Required. Europe Is Leading the Way in Thinking Here	82
The FDA (and EMEA)	84
The FDA and EMEA Both Must Adapt a More Balanced Approach to Antibiotics. Required Trial Designs Must Be Feasible . .	84
Do We Want New Antibiotics for Mild Infections? Is Bacterial Bronchitis in the Setting of Chronic Lung Disease a Mild Infection?	84
The FDA Must Modify Its Guidelines for Clinical Trials in Community Acquired Bacterial Pneumonia	85
The FDA Has to Stop Moving the Goal Posts in Mid-Stream	87
The FDA Has to Level the Playing Field with Generic Antibiotics	88
Congress Needs to Step Back from the FDA Especially Where Science Is Concerned	88
Our Government Needs Access to the Best Advice it Can Get	89
How About a Totally New Approach to Drug Development?	89
Communication Between the Industry and Physicians Is Required, but is Becoming More and More Restricted	91
What Should the Industry Be Doing?	92
The Current Large PhRMA Model Is not Viable. These Giants Need to Divide Themselves into Bite-Size Portions to Survive	93
8 Conclusions	97
Bibliography	101
Index	105